In 2007, Bristol Myers-Squibb, the manufacturer of Abilify, settled a class-action lawsuit where it was charged with illegally marketing off-label use of the drug. The company was also accused of offering doctors kickbacks in the form of money and trips if they prescribed the drug to patients for whom it was not meant.
As of 2014, other lawsuits are pending due to compulsive behavior presented in patients who were prescribed the drug. Compulsive gambling, sex addictions and other compulsive behaviors go away when patients stop taking Abilify.
Abilify is a member of the atypical antipsychotic class of drugs. It was created in 2002 to treat schizophrenia. Two years later, it was approved as a treatment for bipolar disorder, and in 2007, use of the drug to treat depression was approved. The drug works by altering the dopamine and serotonin levels in the brain.
The Food and Drug Administration sent additional warnings about potential side effects that were not on the label and asked Bristol Myers-Squibb to add them to the label. These side effects included a lower resistance to diabetes and hyperglycemia, sudden death in the elderly, suicidal tendencies in younger people and withdrawal symptoms in newborns of mothers who were on the drug during pregnancy.